TECHNOLOGY - M-FOLD™

M-fold Biotech's proprietary M-FOLD™ technology utilises an E. coli expression system designed to enhance expression and to direct the recombinant protein to cytosolic aggregates known as "inclusion bodies”. This enables a yield of up to 10,000 fold higher than seen with conventional recombinant membrane protein expression technologies. Yields using this method are typically between 5-50 mg per litre of cell culture medium. The aggregated recombinant protein is then taken through a series of proprietary purification and refolding steps to generate functional, native protein.

With M-FOLD™, multiple targets or multiple variants of a given membrane protein target can be produced quickly and in a parallel format. To date, more than 200 different GPCRs and ion channels have been cloned and expressed using M-FOLD™. The current rate of success in expression and refolding is more than 75% for any given new protein and has been steadily increasing in the past.

M-FOLD™ is covered by several patents in Europe, the USA and Japan.

M-FOLD™ is the basis of drug discovery technologies such as protein structure analysis and the generation of therapeutic antibodies directed against GPCRs-